Rivaroxaban for the Long-term Treatment of Spontaneous Ovarian Vein Thrombosis Caused by Factor V Leiden Homozygosity

Annals of Pharmacotherapy

Volumn 48, Issue 8, 2014, Pages 1055-1060

  Cook, Rhett M ^a   Rondina, Matthew T ^a   Horton, Devin J ^a  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

anticoagulation; factor V Leiden; ovarian vein thrombosis; rivaroxaban; thrombophilia

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; HEPARIN; HEPARINOID; RIVAROXABAN;

ACUTE KIDNEY FAILURE; ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOT LYSIS; CASE REPORT; FEMALE; FOLLOW UP; HOMOZYGOSITY; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY VEIN; LONG TERM CARE; MONOTHERAPY; OVARIAN VEIN THROMBOSIS; OVARY DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; THROMBOPHILIA; THROMBUS; TREATMENT OUTCOME; VEIN THROMBOSIS;

EID: 84904464844     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028014533304     Document Type: Article

References (30)

1. Coppola A,Tufano A,Cerbone AM,Di Minno G.Inherited thrombophilia: implications for prevention and treatment of venous thromboembolism.Semin Thromb Hemost. 2009;35:683-94.
2. Sveinsdottir SV,Saemundsson Y,Isma N,Gottsater A,Svensson PJ.Evaluation of recurrent venous thromboembolism in patients with factor V Leiden mutation in heterozygous form.Thromb Res. 2012;130:467-471.
3. Kearon C.Influence of hereditary or acquired thrombophilias on the treatment of venous thromboembolism.Curr Opin Hematol. 2012;19:363-370.
4. De Stefano V,Martinelli I.Abdominal thromboses of splanchnic, renal and ovarian veins.Best Pract Res Clin Haematol. 2012;25:253-264.
5. Martinelli I,Franchini M,Mannucci PM.How I treat rare venous thromboses.Blood. 2008;112:4818-4823.
6. Verde F,Johnson PT.One not to miss: ovarian vein thrombosis causing pulmonary embolism with literature review.J Radiol Case Rep. 2012;6:23-28.
7. Gakhal MS,Levy HM,Spina M,Wrigley C.Ovarian vein thrombosis: analysis of patient age, etiology, and side of involvement.Del Medical J. 2013;85:45-50.
8. Sharma P,Abdi S.Ovarian vein thrombosis.Clin Radiol. 2012;67:893-898.
9. Heavrin BS,Wrenn K.Ovarian vein thrombosis: a rare cause of abdominal pain outside the peripartum period.J Emerg Med. 2008;34:67-69.
10. Murphy CS,Parsa T.Idiopathic ovarian vein thrombosis: a rare cause of abdominal pain.Am J Emerg Med. 2006;24:636-637.
11. Simons GR,Piwnica-Worms DR,Goldhaber SZ.Ovarian vein thrombosis.Am Heart J. 1993;126 (3, pt 1): 641-647.
12. Salomon O,Apter S,Shaham D,et al.Risk factors associated with postpartum ovarian vein thrombosis.Thromb Haemost. 1999;82:1015-1019.
13. Tan JW,Howe HS,Chng HH.Ovarian vein thrombosis in Behcet disease.J Clin Rheumatol. 2012;18:89-91.
14. Andre M,Delevaux I,Amoura Z,et al.Ovarian vein thrombosis in the antiphospholipid syndrome.Arthritis Rheum. 2004;50:183-186.
15. Marcovici I,Goldberg E.Ovarian vein thrombosis associated with Crohn's disease: a case report.Am J Obstet Gynecol. 2000;182:743-744.
16. Arkadopoulos N,Dellaportas D,Yiallourou A,Koureas A,Voros D.Ovarian vein thrombosis mimicking acute abdomen: a case report and literature review.World J Emerg Surg. 2011;6:45.
17. Janssen HL,Meinardi JR,Vleggaar FP,et al.Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study.Blood. 2000;96:2364-2368.
18. Wysokinska EM,Hodge D,McBane RD.Ovarian vein thrombosis: incidence of recurrent venous thromboembolism and survival.Thromb Haemost. 2006;96:126-131.
19. Virmani V,Kaza R,Sadaf A,Fasih N,Fraser-Hill M.Ultrasound, computed tomography, and magnetic resonance imaging of ovarian vein thrombosis in obstetrical and nonobstetrical patients.Can Assoc Radiol J. 2012;63:109-118.
20. Schulman S,Crowther MA.How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch.Blood. 2012;119:3016-3023.
21. Cohen AT,Dobromirski M.The use of rivaroxaban for short- and long-term treatment of venous thromboembolism.Thromb Haemost. 2012;107:1035-1043.
22. Brenner B,Hoffman R.Emerging options in the treatment of deep vein thrombosis and pulmonary embolism.Blood Rev. 2011;25:215-221.
23. Kleintjens J,Li X,Simoens S,et al.Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting.Pharmacoeconomics. 2013;31:909-918.
24. Lee S,Anglade MW,Pham D,Pisacane R,Kluger J,Coleman CI.Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.Am J Cardiol. 2012;110:845-851.
25. Lefebvre P,Coleman CI,Bookhart BK,et al.Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism.J Med Econ. 2014;17:52-64.
26. Bauersachs R,Berkowitz SD,Brenner B,et al.Oral rivaroxaban for symptomatic venous thromboembolism.N Engl J Med. 2010;363:2499-2510.
27. van Gogh I,Buller HR,Cohen AT,et al.Idraparinux versus standard therapy for venous thromboembolic disease.N Engl J Med. 2007;357:1094-1104.
28. Schulman S,Kearon C,Kakkar AK,et al.Dabigatran versus warfarin in the treatment of acute venous thromboembolism.N Engl J Med. 2009;361:2342-2352.
29. Abrams PJ,Emerson CR.Rivaroxaban: a novel, oral, direct factor Xa inhibitor.Pharmacotherapy. 2009;29:167-181.
30. Pannach S,Babatz J,Beyer-Westendorf J.Successful treatment of acute portal vein thrombosis with rivaroxaban.Thromb Haemost. 2013;110:626-627.